Come see a special preview of the next-generation PRIMA glasses at the Potsdam Meeting from April 17–18. The new glasses are updated for functionality, including integrated processing and eye tracking. Stop by our booth to connect with our team and learn more about the PRIMA system for GA/AMD.

TechCrunch’s Tim Fernholz reports: “Max Hodak’s Science Corp. is preparing to place its first sensor in a human brain.” Science Advisor Dr. Günel says: “The idea of using natural connections through neurons and creating a biological interface between the electronics and the human brain is genius.”

Come visit us at the VM Retina Meeting 2026 in Munich from Thurs, April 16 – Sat, April 18 – booth #7. Meet our team and see the PRIMA implant, next-gen glasses, and implantation device up close.

Science has won the iF Design Award 2026 for Product Design in the Medical/Healthcare category for the Axon Terminal, part of the Science Ecosystem. Science partnered with the design firm Card79 on the project.

Our CEO Max Hodak joined Juan Benet for a conversation about BCI breakthroughs at Science and how they will benefit patients.

Science Chief Scientific Officer and Co-Founder Alan Mardinly answers the question “What if we could restore vision, communicate directly with the brain, and even extend human life with living, engineered biology?” Click the link in the comments to watch the full episode.

Geographic atrophy due to AMD is the leading cause of irreversible blindness. @nejm.org's Katerina Lin, MD, explains Science’s PRIMA clinical trial and how the system drove significant visual acuity improvements at 12 months. Link in comments.

Arena Magazine profiles Science CEO @maxhodak.bsky.social and details the breakthrough of the PRIMA retinal implant for AMD, the groundbreaking work on Biohybrid, and the new possibilities brain-computer interfaces offer patients. Read the profile in the comments.

As we accelerate the development of our Biohybrid BCI program, we are thrilled to welcome Dr. Murat Günel as Science's new Medical Director for Brain-Computer Interfaces. Dr. Günel is Chair of Neurosurgery at Yale School of Medicine and a Member of the National Academy of Medicine.

Though this sample is invisible to the naked eye, imaging it takes 124 GB of storage, equivalent to ~5x the entire English Wikipedia text.

"People use [AI] every day, but it is still underestimated the degree to which it is going to change everybody’s lives over the next decade. We’re really now starting to see that. [AI agents] are no longer just a curiosity. They’re now having economic impacts that are going to accelerate."

In a new interview, José-Alain Sahel, MD, a senior author of the PRIMA clinical trial now published in @nejm.org, shares his opinion on the resilience required to turn a decades-old concept into clinical reality.

"...we have three programs at Science: our work in the retina [for blindness]...our biohybrid neural interface…and critical care life support”, shared Max Hodak, Science’s CEO. “If Medtronic was started in 2021, what are the projects that they would be taking on for the next 20 years?”

"I think there's going to be a bunch of BCI companies going after different applications where different types of probes will make sense. To me, it firmly feels like we're in the takeoff era." Science founder and CEO Max Hodak joined YCombinator to talk about the future of brain-computer interfaces

Science's PRIMA clinical trials are expanding to Australia, and will include inherited retinal diseases, such as Stargardt disease and retinitis pigmentosa.

We’ve closed a $230 million Series C financing. The deal was oversubscribed with demand in excess of our capital needs, and brings the total capital invested into the company to approximately $490 million since our founding in 2021.

We’ve closed a $230 million Series C financing with participation from Khosla Ventures, Lightspeed Venture Partners, Y Combinator, IQT, and Quiet Capital, all pre-existing investors in Science, among others.

Robots can place atoms with sub-micron precision, but nothing beats the human touch when it comes to handling live neural tissue.

The universe within Science biohybrid cells.

We have partnered with Neurosoft, a neural data company developing ultra-soft, flexible neural probes to achieve full cortical coverage powering foundation models of the brain, to grant them access to Science’s world-class clinical-grade neural engineering capabilities known as the Science Ecosystem

POV: you’re about to evaporate gold. This machine uses an electron beam to evaporate metal into a vapor that condenses onto a substrate, an essential step when manufacturing flexible electronics.

Science Founder and CEO, Max Hodak, has been named to 2026 @TIME 100 Health. TIME writes: “It’s no small thing to bring eyesight to the blind—or nearly blind. But that’s what Max Hodak, founder and CEO of Science Corporation in California, has helped achieve.”

In a new interview, Frank Holz, MD, lead author and scientific coordinator of the PRIMA clinical trial now published in @nejm.org, shares his opinion on the new reality of restoring vision to clinical trial patients who had been functionally blind.

Frank Brodie, MD, Science’s Medical Director for Vision and PRIMA, joined @brightfocus.bsky.social to discuss the PRIMA retinal implant, the first treatment shown in clinical trials to restore functional vision for geographic atrophy due to AMD: www.brightfocus.org/resource/can...

Science founder and CEO @maxhodak.bsky.social sat down with the Berggruen Institute’s @futurologypod.bsky.social to discuss our work to improve the human condition. Watch the full conversation here: youtu.be/1PlnrJ7t6AA

Frank Brodie, MD, Science’s Medical Director for Vision and PRIMA, will join @brightfocus.bsky.social for a discussion titled “Can Retinal Implants Restore Vision?” Learn more about the conversation and how to join below.

In a @nejm.org editorial, Jacque Duncan, M.D. details the scientific foundations of PRIMA, describing it as the first treatment shown in clinical trials to successfully restore functional vision to certain patients suffering from geographic atrophy due to age-related macular degeneration.

“We want to build tools that empower individuals to have agency over their life.” In a video with the Abundance Institute, @maxhodak.bsky.social explains how neural engineering enables us to restore lost function and, in doing so, return agency to people who have lost it.

Our PRIMA retinal implant is about the size of a pinhead and thinner than a human hair. The chip “represents the first treatment to restore vision in persons with advanced geographic atrophy” in clinical trials, according to a new editorial in @nejm.org

Ophthalmology Times reports on a @nejm.org editorial describing our PRIMA retinal implant as “the first treatment to restore vision” in clinical trials for certain patients with advanced geographic atrophy associated with age-related macular degeneration.

An editorial published today in @nejm.org writes that our PRIMA implant is the first treatment in clinical trials to successfully restore functional vision to certain patients suffering from geographic atrophy due to age-related macular degeneration. Read the editorial: www.nejm.org/doi/full/10....

“Blind patients are actually able to have meaningful central vision restoration, which has never been done before.” – Mahi Muqit, PhD, co-author of the New England Journal of Medicine paper, discussing clinical trial results of our PRIMA retinal implant

Our PRIMA retinal implant is designed to replace the function of light-sensitive cells in the eye that have been lost due to advanced degenerative retinal diseases, restoring functional central vision in clinical trials Here's what the world looks like to a PRIMA patient science.xyz/technologies...

In clinical trials, our PRIMA retinal implant restored functional vision to patients suffering from geographic atrophy due to age-related macular degeneration. Take a look inside the labs.

At a recent Stanford Icons dinner, @maxhodak.bsky.social shared his perspective on neural engineering and the future of brain–computer interfaces—from biohybrid neural interfaces built with living neurons to the long-term pursuit of conscious machines.

Today we announced Vessel, a project focused on rethinking perfusion from the ground up. Our founder and CEO @maxhodak.bsky.social spoke with @wired.com’s @emilymullin.bsky.social about how neural interfaces and Vessel are both longevity technologies, and that is the goal of Science.

As we work to restore, improve, and extend life, we are making important leadership appointments. Alan Mardinly will serve as our first Chief Scientific Officer. Frank Brodie, M.D. will serve as Medical Director for Vision and PRIMA.

Welcome Darius Shahida, our new Chief Strategy Officer. As we continue to accelerate into our mission to transcend the limits of biology, Darius brings deep experience in strategic growth, capital markets, and scaling category-defining technology companies. Read the press release in the comments.

@techcrunch.com's @connieloizos.bsky.social highlights our founder and CEO @maxhodak.bsky.social’s path from early brain–machine interface research to how his perspective continues to shape our approach to neural engineering.

Science founder and CEO @maxhodak.bsky.social joined @connieloizos.bsky.social at @techcrunch.com’s StrictlyVC in Palo Alto to explore the future of neural engineering – from restoring vision to building technologies that could reshape how humans think, learn, and interface with the world.

In our clinical trial, participants with geographic atrophy experienced something previously thought impossible: meaningful restoration of central vision. Learn more about our PRIMA retinal implant here: science.xyz/technologies...

What could you do with world-class neurotech that fits in the palm of your hand? The Science Ecosystem has the hardware and software needed to develop next-generation neural engineering therapies. Learn more here: science.xyz/company/cont...

We are neuroscientists, biologists, cell engineers, electrical engineers, mechanical engineers, software engineers, IC designers, MEMS engineers, clinicians, operators, and more. We are Science. Learn more about our work here: science.xyz

Thank you to the many scientists, physicians, and researchers who visited us at the Society for Neuroscience’s (@sfn.org) Annual Meeting 2025 and shared their excitement for our work building a brighter tomorrow enabled by neural engineering. If you missed us at #SfN25, learn more here: science.xyz

We develop a full range of technologies required for modern neural engineering, building devices aimed at restoring vision, communication and cognition to improve the human condition. Visit us at Booth #3101 at the Society for Neuroscience’s (@sfn.org) Annual Meeting 2025 to learn more. #SfN25

A first glimpse from #SfN2025: our next-gen PRIMA glasses. The glasses feature an embedded camera and infrared projector that send light signals to our PRIMA retinal implant, providing both power and data. Experience the PRIMA glasses and preview the next-generation design at Booth #3101.

Members of the Science team are at the Society for Neuroscience’s (@sfn.org) Annual Meeting 2025 connecting with some of the brightest minds in neuroscience. Visit us at Booth #3101 and learn more about our unique approach to brain-computer interfaces. #SfN25

Come meet Science cofounder and Chief Scientific Officer Alan Mardinly at Booth #3101 at the Society for Neuroscience’s (@sfn.org) Annual Meeting 2025 and learn more about our unique biohybrid approach to brain-computer interfaces. #SfN25

We’re at the Society for Neuroscience’s (@sfn.org) Annual Meeting 2025 to share our work advancing brain-computer interfaces, from our PRIMA retinal implant to our Science Ecosystem full stack technology platform for neural engineering. Visit us at Booth #3101 to learn more. #SfN25

Science founder and CEO @maxhodak.bsky.social joined Jordi Hays and John Coogan on TBPN to talk about our work on brain-computer interfaces, the success of our PRIMA retinal implant, and how the next decade may look very different from the last.